Memantine in moderate-to-severe Alzheimer's disease.

By B. Reisberg, R. Doody, A. Stöffler, Frederick A. Schmitt, S. Ferris, H. Möbius. New England Journal of Medicine, 2003

1,019 citations recorded by the source corpus.

Subfields: Cellular and Molecular Neuroscience, Physiology, Psychiatry and Mental health

View Paper: https://www.semanticscholar.org/paper/be6bbf7399c526900b6c1bee910497cbfd5b3b65

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cellular and Molecular Neuroscience

1. G. Sanacora
2. John H. Krystal
3. Husseini K. Manji
4. K. Al-Harbi
5. R. Duman

Citations in the corpus

• Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders (2008, background): “, and is approved for the treatment of moderate to severe Alzheimer's disease, in which it has been shown to enhance cognition and minimize clinical deterioration in patients with Alzheimer's disease, vascular dementia or mixed dementi”
• Hippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine for Patients With Brain Metastases: Phase III Trial NRG Oncology CC001. (2020, background): “Memantine is an N-methyl-D-aspartate (NMDA) receptor antagonist that blocks pathologic excessive stimulation of NMDA receptors and has been shown to be beneficial in dementia and neuroprotective in preclinical models of brain irradiation.(6,7) In a placebo-controlled phase III trial, prophylactic me”